Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Mahmoud , Amr A A ^a   Elshazly, Shimaa M ^a  

^a Zagazig University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FENOFIBRATE; GLUCOSE; GLUTATHIONE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; MALONALDEHYDE; TRIACYLGLYCEROL; URIC ACID; URSODEOXYCHOLIC ACID; XANTHINE OXIDASE; FRUCTOSE; GLUCOSE BLOOD LEVEL; NOS2 PROTEIN, RAT; NOS3 PROTEIN, RAT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; MORNING DOSAGE; NONHUMAN; OXIDATIVE STRESS; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VISCOELASTICITY; WEIGHT GAIN; ANIMAL; BLOOD; BLOOD PRESSURE; BODY WEIGHT; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL; FENOFIBRATE; FRUCTOSE; GLUTATHIONE; GLYCOSYLATION END PRODUCTS, ADVANCED; INSULIN; INSULIN RESISTANCE; MALE; MALONDIALDEHYDE; METABOLIC SYNDROME X; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; RATS; RATS, WISTAR; TRIGLYCERIDES; URIC ACID; URSODEOXYCHOLIC ACID;

EID: 84923001119     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106993     Document Type: Article

References (71)

1. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607.
2. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes care 24: 683-689.
3. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM (2003) The metabolic syndrome as predictor of type 2 diabetes: The San Antonio heart study. Diabetes care 26: 3153-3159.
4. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, et al. (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110: 1245-1250.
5. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414: 782-787.
6. Laville M, Nazare JA (2009) Diabetes, insulin resistance and sugars. Obesity reviews : An official journal of the International Association for the Study of Obesity 10 Suppl 1: 24-33.
7. Hulman S, Falkner B (1994) The effect of excess dietary sucrose on growth, blood pressure, and metabolism in developing Sprague-Dawley rats. Pediatric research 36: 95-101.
8. Hwang IS, Ho H, Hoffman BB, Reaven GM (1987) Fructose-induced insulin resistance and hypertension in rats. Hypertension 10: 512-516.
9. Tobey TA, Mondon CE, Zavaroni I, Reaven GM (1982) Mechanism of insulin resistance in fructose-fed rats. Metabolism: clinical and experimental 31: 608- 612.
10. Tran LT, Yuen VG, McNeill JH (2009) The fructose-fed rat: A review on the mechanisms of fructose-induced insulin resistance and hypertension. Molecular and cellular biochemistry 332: 145-159.
11. Chou CL, Lai YH, Lin TY, Lee TJ, Fang TC (2011) Aliskiren prevents and ameliorates metabolic syndrome in fructose-fed rats. Archives of medical science : AMS 7: 882-888.
12. Nakagawa T, Tuttle KR, Short RA, Johnson RJ (2005) Hypothesis: fructoseinduced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nature clinical practice Nephrology 1: 80-86.
13. Iyer SN, Katovich MJ (1994) Effect of chronic losartan potassium treatment on fructose-induced hypertension. Life sciences 55: 139-144.
14. Juan CC, Fang VS, Hsu YP, Huang YJ, Hsia DB, et al. (1998) Overexpression of vascular endothelin-1 and endothelin-A receptors in a fructose-induced hypertensive rat model. Journal of hypertension 16: 1775-1782.
15. Verma S, Bhanot S, McNeill JH (1999) Sympathectomy prevents fructoseinduced hyperinsulinemia and hypertension. European journal of pharmacology 373: 1-4.
16. Miller AW, Katakam PV, Ujhelyi MR (1999) Impaired endothelium-mediated relaxation in coronary arteries from insulin-resistant rats. Journal of vascular research 36: 385-392.
17. Luketic VA, Sanyal AJ (1994) The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease. The Gastroenterologist 2: 74-79.
18. Makino I, Tanaka H (1998) From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament. Journal of gastroenterology and hepatology 13: 659-664.
19. Angulo P (2002) Use of ursodeoxycholic acid in patients with liver disease. Current gastroenterology reports 4: 37-44.
20. Ma J, Nakajima T, Iida H, Iwasawa K, Terasawa K, et al. (2003) Inhibitory effects of ursodeoxycholic acid on the induction of nitric oxide synthase in vascular smooth muscle cells. European journal of pharmacology 464: 79-86.
21. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, et al. (2011) A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. Journal of hepatology 54: 1011-1019.
22. Tsuchida T, Shiraishi M, Ohta T, Sakai K, Ishii S (2012) Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. Metabolism: clinical and experimental 61: 944-953.
23. Sinisalo J, Vanhanen H, Pajunen P, Vapaatalo H, Nieminen MS (1999) Ursodeoxycholic acid and endothelial-dependent, nitric oxide-independent vasodilatation of forearm resistance arteries in patients with coronary heart disease. Br J Clin Pharmacol 47: 661-665.
24. Vamecq J, Latruffe N (1999) Medical significance of peroxisome proliferatoractivated receptors. Lancet 354: 141-148.
25. Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK (2005) Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes care 28: 1419-1424.
26. Sampathkumar R, Balasubramanyam M, Rema M, Premanand C, Mohan V (2005) A novel advanced glycation index and its association with diabetes and microangiopathy. Metabolism: clinical and experimental 54: 1002-1007.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412- 419.
28. Satoh K (1978) Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clinica chimica acta; international journal of clinical chemistry 90: 37-43.
29. Beutler E, Duron O, Kelly BM (1963) Improved method for the determination of blood glutathione. The Journal of laboratory and clinical medicine 61: 882- 888.
30. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-Time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
31. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP (2004) National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110: 1251-1257.
32. Le KA, Tappy L (2006) Metabolic effects of fructose. Current opinion in clinical nutrition and metabolic care 9: 469-475.
33. Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ (2002) Fructose, weight gain, and the insulin resistance syndrome. The American journal of clinical nutrition 76: 911-922.
34. Bray GA, Nielsen SJ, Popkin BM (2004) Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. The American journal of clinical nutrition 79: 537-543.
35. De Caestecker, JS, Jazrawi RP, Petroni ML, Northfield TC (1991) Ursodeoxycholic acid in chronic liver disease. Gut 32: 1061-1065.
36. Comar KM, Sterling RK (2006) Review article: Drug therapy for non-Alcoholic fatty liver disease. Aliment Pharmacol Ther 23: 207-215.
37. Kars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, et al. (2010) Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes 59: 1899-1905.
38. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, et al. (2001) Peroxisome proliferator-Activated receptor (PPAR)-Alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 50: 411-417.
39. Matsui H, Okumura K, Kawakami K, Hibino M, Toki Y, et al. (1997) Improved insulin sensitivity by bezafibrate in rats: relationship to fatty acid composition of skeletal-muscle triglycerides. Diabetes 46: 348-353.
40. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, et al. (2000) Peroxisome proliferator-Activated receptor alpha activators improve insulin sensitivity and reduce adiposity. The Journal of biological chemistry 275: 16638-16642.
41. Tabernero A, Schoonjans K, Jesel L, Carpusca I, Auwerx J, et al. (2002) Activation of the peroxisome proliferator-Activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC pharmacology 2: 10.
42. Ryan KE, McCance DR, Powell L, McMahon R, Trimble ER (2007) Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 194: 123-130.
43. Sanchez-Lozada LG, Tapia E, Jimenez A, Bautista P, Cristobal M, et al. (2007) Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. American journal of physiology Renal physiology 292: 423-429.
44. Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV (2004) Cardiac lipids and antioxidant status in high fructose rats and the effect of alpha-lipoic acid. Nutrition, metabolism, and cardiovascular diseases : NMCD 14: 351-357.
45. Cavarape A, Feletto F, Mercuri F, Quagliaro L, Daman G, et al. (2001) Highfructose diet decreases catalase mRNA levels in rat tissues. Journal of endocrinological investigation 24: 838-845.
46. Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, Soto V, Avila-Casado C, et al. (2008) Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. American journal of physiology Renal physiology 294: 710-718.
47. Hallfrisch J (1990) Metabolic effects of dietary fructose. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 4: 2652-2660.
48. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, et al. (2006) A causal role for uric acid in fructose-induced metabolic syndrome. American journal of physiology Renal physiology 290: 625-631.
49. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, et al. (2005) Hyperuricemia induces endothelial dysfunction. Kidney international 67: 1739- 1742.
50. Roy D, Perreault M, Marette A (1998) Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. The American journal of physiology 274: 692-699.
51. Delbosc S, Paizanis E, Magous R, Araiz C, Dimo T, et al. (2005) Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis 179: 43-49.
52. Polizio AH, Gonzales S, Munoz MC, Pena C, Tomaro ML (2006) Behaviour of the anti-oxidant defence system and heme oxygenase-1 protein expression in fructose-hypertensive rats. Clinical and experimental pharmacology & physiology 33: 734-739.
53. Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. The American journal of physiology 271: 1424- 1437.
54. Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, et al. (1999) Abnormal biopterin metabolism is a major cause of impaired endotheliumdependent relaxation through nitric oxide/O2- imbalance in insulin-resistant rat aorta. Diabetes 48: 2437-2445.
55. Spiekermann S, Landmesser U, Dikalov S, Bredt M, Gamez G, et al. (2003) Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endotheliumdependent vasodilation. Circulation 107: 1383-1389.
56. Ulker S, McMaster D, McKeown PP, Bayraktutan U (2003) Impaired activities of antioxidant enzymes elicit endothelial dysfunction in spontaneous hypertensive rats despite enhanced vascular nitric oxide generation. Cardiovascular research 59: 488-500.
57. Hink U, Li H, Mollnau H, Oelze M, Matheis E, et al. (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circulation research 88: 14-22.
58. Mahmoud MF, Hassan NA, El-Bassossy HM, Fahmy A (2013) Quercetin protects against diabetes-induced exaggerated vasoconstriction in rats: effect on low grade inflammation. PloS one 8: e63784.
59. Mahmoud MF, El-Nagar M, El-Bassossy HM (2012) Anti-inflammatory effect of atorvastatin on vascular reactivity and insulin resistance in fructose fed rats. Archives of pharmacal research 35: 155-162.
60. Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114: 597-605.
61. Ardestani A, Yazdanparast R (2007) Cyperus rotundus suppresses AGE formation and protein oxidation in a model of fructose-mediated protein glycoxidation. International journal of biological macromolecules 41: 572-578.
62. Vlassara H (2001) The AGE-receptor in the pathogenesis of diabetic complications. Diabetes/metabolism research and reviews 17: 436-443.
63. Miller A, Adeli K (2008) Dietary fructose and the metabolic syndrome. Current opinion in gastroenterology 24: 204-209.
64. Sokolovic D, Nikolic J, Kocic G, Jevtovic-Stoimenov T, Veljkovic A, et al. (2013) The effect of ursodeoxycholic acid on oxidative stress level and DNase activity in rat liver after bile duct ligation. Drug Chem Toxicol 36: 141-148.
65. Tessari P, Coracina A, Cosma A, Tiengo A (2009) Hepatic lipid metabolism and non-Alcoholic fatty liver disease. Nutrition, metabolism, and cardiovascular diseases : NMCD 19: 291-302.
66. Hodel C (2002) Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicology letters 128: 159-168.
67. Okada M, Sano F, Ikeda I, Sugimoto J, Takagi S, et al. (2009) Fenofibrateinduced muscular toxicity is associated with a metabolic shift limited to type-1 muscles in rats. Toxicologic pathology 37: 517-520.
68. Ho CY, Kuo TH, Chen TS, Tsay SH, Chang FY, et al. (2004) Fenofibrateinduced acute cholestatic hepatitis. Journal of the Chinese Medical Association : JCMA 67: 245-247.
69. Rigal J, Furet Y, Autret E, Breteau M (1989) [Severe mixed hepatitis caused by fenofibrate? A review of the literature apropos of a case]. La Revue de medecine interne/fondee par la Societe nationale francaise de medecine interne 10: 65-67.
70. Hempfling W, Dilger K, Beuers U (2003) Systematic review: ursodeoxycholic acid-Adverse effects and drug interactions. Alimentary pharmacology & therapeutics 18: 963-972.
71. Kondrackiene J, Beuers U, Kupcinskas L (2005) Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129: 894-901.